Feasibility and accuracy of SPECT myocardial perfusion imaging in end-stage lung disease.
Aged
Coronary Angiography
/ methods
Coronary Artery Disease
/ diagnostic imaging
Cross-Sectional Studies
Feasibility Studies
Female
Humans
Lung Neoplasms
/ diagnostic imaging
Male
Middle Aged
Myocardial Perfusion Imaging
/ methods
Percutaneous Coronary Intervention
Purines
/ administration & dosage
Pyrazoles
/ administration & dosage
Reproducibility of Results
Retrospective Studies
Tomography, Emission-Computed, Single-Photon
/ methods
COPD
ILD
SPECT
coronary artery disease
myocardial perfusion imaging
stress testing
Journal
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
ISSN: 1532-6551
Titre abrégé: J Nucl Cardiol
Pays: United States
ID NLM: 9423534
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
16
11
2018
accepted:
25
07
2019
pubmed:
21
8
2019
medline:
31
8
2021
entrez:
21
8
2019
Statut:
ppublish
Résumé
Coronary artery disease (CAD) is associated with increased mortality in patients with chronic lung disease. However, non-invasive diagnostic of CAD is difficult, especially in patients with more advanced disease. Therefore, we aimed to assess the feasibility and accuracy of SPECT-myocardial perfusion imaging (MPI) stress testing with regadenoson in patients with end-stage lung disease (ELD) undergoing assessment of stable CAD. Between January 2012 and May 2018, 102 patients with ELD, who were referred to our institution for lung transplant evaluation, were assessed retrospectively. All patients underwent both stress SPECT-MPI as well as coronary angiography. The mean age in our population was 57±6 years. All patients had severe pulmonary function impairment. During stress SPECT-MPI 14 patients (14%) reported regadenoson-related symptoms, but only 2 patients (2%) required medical treatment. Coronary angiography revealed obstructive CAD in 20 patients (20%). Among those, 5 patients had abnormal SPECT-MPI and PCI was performed in 3 patients accordingly. In 14 patients with obstructive CAD, revascularization was deferred based on normal SPECT-MPI findings. SPECT-MPI using regadenoson is well tolerated in patients with ELD and can help to make decisions about coronary revascularization before lung transplant.
Sections du résumé
BACKGROUND
Coronary artery disease (CAD) is associated with increased mortality in patients with chronic lung disease. However, non-invasive diagnostic of CAD is difficult, especially in patients with more advanced disease. Therefore, we aimed to assess the feasibility and accuracy of SPECT-myocardial perfusion imaging (MPI) stress testing with regadenoson in patients with end-stage lung disease (ELD) undergoing assessment of stable CAD.
METHODS
Between January 2012 and May 2018, 102 patients with ELD, who were referred to our institution for lung transplant evaluation, were assessed retrospectively. All patients underwent both stress SPECT-MPI as well as coronary angiography.
RESULTS
The mean age in our population was 57±6 years. All patients had severe pulmonary function impairment. During stress SPECT-MPI 14 patients (14%) reported regadenoson-related symptoms, but only 2 patients (2%) required medical treatment. Coronary angiography revealed obstructive CAD in 20 patients (20%). Among those, 5 patients had abnormal SPECT-MPI and PCI was performed in 3 patients accordingly. In 14 patients with obstructive CAD, revascularization was deferred based on normal SPECT-MPI findings.
CONCLUSIONS
SPECT-MPI using regadenoson is well tolerated in patients with ELD and can help to make decisions about coronary revascularization before lung transplant.
Identifiants
pubmed: 31428982
doi: 10.1007/s12350-019-01851-4
pii: 10.1007/s12350-019-01851-4
doi:
Substances chimiques
Purines
0
Pyrazoles
0
regadenoson
2XLN4Y044H
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
903-911Commentaires et corrections
Type : CommentIn